Explore the vast range of titles available.

With the increasing global emphasis on green energy and sustainable development goals, the electrocatalytic oxygen evolution reaction (OER) is gradually becoming a crucial focus in research on water oxidation for hydrogen generation. However, its complicated reaction processes associated with its high energy barrier severely limit the efficiency of energy conversion. Recently, layered double hydroxide (LDH) has been considered as one of the most promising catalysts in alkaline media. Nonetheless, lacking a deep insight into the kinetic process of the electrocatalytic OER process is detrimental to the further optimization of LDH catalysts. Therefore, monitoring the catalytic reaction kinetic process via surface-sensitive in situ spectroscopy is especially important. In particular, the in situ Raman technique is capable of providing fingerprint information for surface species and intermediates in the operating environment. From the perspective of Raman spectroscopy, this paper provides an exhaustive overview of research progress in in situ Raman for the characterization of the catalytic mechanism of LDH catalysts, providing theoretical guidance for designing LDH materials. Finally, we present an incisive discussion on the challenges of the electrocatalytic in situ Raman technique and its future development trend.

The creation of metal nanoclusters with dimensions ranging from subnanometre to ~2 nm for heterogeneous catalysis has received substantial attention. However, synthesizing these structures while retaining surface activity and avoiding aggregation is challenging. Here, we report a reverse double-solvents approach that enables encapsulation of highly catalytically active Pd nanoclusters inside the newly formed discrete organic molecular cage, RCC3. By encapsulating within the open cavities of soluble RCC3 cages, the obtained Pd nanocluster cores are produced with precisely controlled size (~0.72 nm) and show high solubility, excellent dispersibility and accessibility in solution, presenting significantly enhanced catalytic activities towards various liquid-phase catalytic reactions. Moreover, owing to the effective confinement of cage cavities, the as-prepared Pd nanoclusters possess excellent stability and durability. The strategy of encapsulation of metal nanoclusters within soluble porous organic cages is promising for developing stable and active catalysts. Small metal nanoclusters often display high catalytic activity, but also low stability due to aggregation. Here, Xu and co-workers show that subnanometre Pd clusters can be contained within porous organic cages. Not only do the particles retain high catalytic activity, they also show excellent solubility and stability.

Background Recently, the potential role of gut microbiome in metabolic diseases has been revealed, especially in cardiovascular diseases. Hypertension is one of the most prevalent cardiovascular diseases worldwide, yet whether gut microbiota dysbiosis participates in the development of hypertension remains largely unknown. To investigate this issue, we carried out comprehensive metagenomic and metabolomic analyses in a cohort of 41 healthy controls, 56 subjects with pre-hypertension, 99 individuals with primary hypertension, and performed fecal microbiota transplantation from patients to germ-free mice. Results Compared to the healthy controls, we found dramatically decreased microbial richness and diversity, Prevotella -dominated gut enterotype, distinct metagenomic composition with reduced bacteria associated with healthy status and overgrowth of bacteria such as Prevotella and Klebsiella , and disease-linked microbial function in both pre-hypertensive and hypertensive populations. Unexpectedly, the microbiome characteristic in pre-hypertension group was quite similar to that in hypertension. The metabolism changes of host with pre-hypertension or hypertension were identified to be closely linked to gut microbiome dysbiosis. And a disease classifier based on microbiota and metabolites was constructed to discriminate pre-hypertensive and hypertensive individuals from controls accurately. Furthermore, by fecal transplantation from hypertensive human donors to germ-free mice, elevated blood pressure was observed to be transferrable through microbiota, and the direct influence of gut microbiota on blood pressure of the host was demonstrated. Conclusions Overall, our results describe a novel causal role of aberrant gut microbiota in contributing to the pathogenesis of hypertension. And the significance of early intervention for pre-hypertension was emphasized.

Downsizing noble metal nanoparticles,such as Pt,is an essential goal for many catalytic reactions.A non-noble metal sacrificial approach was used to immobilize monodispersed Pt nanoparticles （NPs） with a mean size of 1.2 nm on reduced graphene oxide （RGO）.ZnO co-precipitated with Pt NPs and subsequently sacrificed by acid etching impedes the diffusion of Pt atoms onto the primary Pt particles and also their aggregation during the reduction of precursors.The resulting ultrafine Pt nanoparticles exhibit high activity （a turnover frequency of 284 min-1 at 298 K） in the hydrolytic dehydrogenation of ammonia borane.The non-noble metal sacrificial approach is demonstrated as a general approach to synthesize well-dispersed noble metal NPs for catalysis.

The liquid chemical hydrogen storage technology has great potentials for high-density hydrogen storage and transportation at ambient temperature and pressure. However, its commercial applications highly rely on the high-performance heterogeneous dehydrogenation catalysts, owing to the dehydrogenation difficulty of chemical hydrogen storage materials. In recent years, the chemists and materials scientists found that the supported metal nanoparticles (MNPs) can exhibit high catalytic activity, selectivity, and stability for the dehydrogenation of chemical hydrogen storage materials, which will clear the way for the commercial application of liquid chemical hydrogen storage technology. This review has summarized the recent important research progress in the MNP-catalyzed liquid chemical hydrogen storage technology, including formic acid dehydrogenation, hydrazine hydrate dehydrogenation and ammonia borane dehydrogenation, discussed the urgent challenges in the key field, and pointed out the future research trends.

Background This study focused on the roles of lncRNA THRIL in coronary atherosclerotic heart disease (CAD) through regulating AKT signaling pathway and directly interacting with FUS. Methods QRT-PCR was conducted to detect the expression of THRIL in CAD blood samples and endothelial progenitor cells (EPCs). Cell autophagy of EPCs was examined through Cyto-ID Autophagy Detection Kit. CCK-8 assay and flow cytometry were carried out to assess cell viability and apoptosis under various interference conditions. Western blotting was conducted to detect the expression of interest proteins. The expression levels of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were measured by qRT-PCR. The direct interactions between HCG18 and FUS was confirmed through RNA electrophoretic mobility shift assay (RNA EMSA) and RNA immunoprecipitation (RIP) assay. Results THRIL was upregulated in CAD blood samples and EPCs. Knockdown of THRIL in EPCs promoted cell viability, inhibited cell autophagy and further suppressed the development of CAD. Over-expression of THRIL induced inactivation of AKT pathway, while knockdown of THRIL played reversed effects. THRIL directly interacted with FUS protein and knockdown of FUS reversed the over-expressing effect of THRIL on cell proliferation, autophagy and the status of AKT pathway. Conclusion THRIL inhibits the proliferation and mediates autophagy of endothelial progenitor cells via AKT pathway and FUS.

IMPACT STATEMENT This article systematically reviews the recent breakthroughs of the heteroatom-doped RuO2 electrocatalysts based on a classification framework for doping strategies and presents the current challenges and the future opportunities.

Background Atrial fibrillation (AF) is associated with circulating inflammation. Short-chain fatty acids (SCFAs) derived from gut microbiota (GM) regulate leukocyte function and inhibit the release of inflammatory cytokines, which are partly mediated by the G-protein-coupled receptor 43 (GPR43) signaling. This study aimed to investigate the expression of GPR43/NOD-like receptors family pyrin domain containing 3 (NLRP3) in leukocytes and the interaction with intestinal SCFAs levels in AF patients. Methods Expressions of GPR43 and NLRP3 mRNA in peripheral blood leukocytes from 23 AF patients and 25 non-AF controls were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Expressions of leukocyte GPR43 and NLRP3 protein were evaluated by western blot analysis. The levels of plasma IL-1β were measured by enzyme-linked immunosorbent assay (ELISA). The fecal SCFAs levels based on GC/MS metabolome of corresponding 21 controls and 14 AF patients were acquired from our published dataset. To evaluate the expression of NLRP3 and GPR43 and the release of IL-1β, human THP-1 cells were stimulated with or without SCFAs (acetate, propionate, and butyrate), lipopolysaccharide (LPS), and nigericin in vitro, respectively. Results Compared to the controls, the mRNA expression in peripheral leukocytes was significantly reduced in AF patients ( P  = 0.011) coupled with the increase in downstream leukocyte NLRP3 mRNA expression ( P  = 0.007) and plasma IL-1β levels ( P  < 0.001), consistent with changes in GPR43 and NLRP3 protein expression. Furthermore, leukocyte GPR43 mRNA levels were positively correlated with fecal GM-derived acetic acid ( P  = 0.046) and negatively correlated with NLRP3 mRNA expression ( P  = 0.024). In contrast to the negative correlation between left atrial diameter (LAD) and GPR43 ( P  = 0.008), LAD was positively correlated with the leukocyte NLRP3 mRNA levels ( P  = 0.024). Subsequent mediation analysis showed that 68.88% of the total effect of intestinal acetic acid on AF might be mediated by leukocyte GPR43/NLRP3. The constructed GPR43–NLRP3 score might have a predictive potential for AF detection (AUC = 0.81, P  < 0.001). Moreover, SCFAs treatment increased GPR43 expression and remarkably reduced LPS/nigericin-induced NLRP3 expression and IL-1β release in human THP-1 cells in vitro. Conclusions Disrupted interactions between GPR43 and NLRP3 expression in peripheral blood leukocytes, associated with reduced intestinal GM-derived SCFAs, especially acetic acid, may be involved in AF development and left atrial enlargement by enhancing circulating inflammation.

Background The gut microbiota provides health benefits in humans by producing short-chain fatty acids (SCFAs), whose deficiency causes multiple disorders and inflammatory diseases. However, gut bacteria producing SCFAs in patients with atrial fibrillation (AF), an arrhythmia with increasing prevalence, have not been reported. To investigate major gut microbial organisms related to SCFA synthesis, SCFAs-associated KEGG orthologues (KOs), enzymatic genes, and potential producers were examined according to metagenomic data-mining in a northern Chinese cohort comprising 50 non-AF control and 50 AF patients. Results Compared with non-AF controls, individuals with AF had marked differences in microbial genes involved in SCFA-related synthesis, including 125 KOs and 5 SCFAs-related enzymatic genes. Furthermore, there were 10 species that harbored SCFA-synthesis related enzymatic genes, and were markedly decreased in the gut of AF patients. Notably, discriminative features about SCFA-synthesis related function, including 8 KOs (K01752, K01738, K00175, K03737, K01006, K01653, K01647 and K15023), 4 genes ( menI , tesB , yciA and CO dehydrogenase acetyl-CoA synthase complex ) and 2 species ( Coprococcus catus and Firmicutes bacterium CAG:103 ), were selected as key factors based on LASSO analysis. Furthermore, PLS-SEM analysis showed that 72.8 and 91.14 % of the overall effects on gut microbiota diversity and key species on AF, respectively, were mediated by the key KOs. Meanwhile, 46.31 % of the total effects of SCFA-synthesis related function on left atrial enlargement was mediated by hsCRP. Upon incorporation of clinical properties in AF, the KO score was still significantly associated with AF incidence (OR = 0.004, P = 0.001). Conclusions The current study revealed that dysbiotic gut microbiota in AF is coupled with disrupted SCFA-synthesis related genes, characterized by decreased abundances of KEGG orthologues, synthesis enzymatic genes and harboring species.

Background The gut bacteria-derived metabolite trimethylamine-N-oxide (TMAO) has been discussed in various cardiometabolic diseases. However, evidence characterizing the microbial population responsible for TMAO accumulation in patients with atrial fibrillation (AF), an increasingly prevalent arrhythmia, is yet lacking. In order to understand the key gut microorganisms that produce TMAO in AF, trimethylamine (TMA)-synthesis enzymes and metabolic pathways, as well as the potential TMA-producers in gut microbiome were assessed based on metagenomic data-mining in a northern Chinese cohort consisting of 50 non-AF controls and 50 patients with different types of AF. Results Compared to the control subjects, AF patients showed a marked increase in the microbial genes underlying TMA formation in the gut, which included 12 potential TMA-synthesis functional orthologs and 1 module. The specific bacterial genes, including choline-TMA lyase , carnitine monooxygenase , glycine betaine reductase , and TMAO reductase , were elevated in the gut of AF patients. Furthermore, 16 genera were assigned and significantly correlated with TMA-enzymatic genes, where 9 genera were remarkably enriched in the gut communities of AF patients. Neither of these TMA-synthesis pathways nor the microbial players showed a significant discrepancy between different types of AF in the current cohort. These gut microbes might participate in the formation of TMA by activating the key TMA-synthesis enzymes and contributing to the functional pathways in AF patients. Conclusions The present study provides an in-depth insight into the potential bacteria and metabolic pathways involved in TMA production in the gut of AF patients. These findings emphasize a key role of the gut bacteria in driving TMAO formation during AF pathogenesis, thereby indicating its therapeutic potential as an intervention strategy of AF by targeting TMA-synthesis pathways and dysbiotic gut microbiota.